Literature DB >> 16766049

Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery.

Mihály Hajós1.   

Abstract

Current observations indicate that dysfunction of neuronal circuitry dynamics contributes to the abnormal information processing in the brain in schizophrenia. It is presumed that disrupted auditory gating, abnormal P300-evoked potentials and deficits in mismatch negativity in schizophrenic patients indicate impaired processing of information. Recently, abnormalities in neuronal synchrony and oscillatory activity have been postulated as the mechanisms that underlie the distorted perception and cognitive dysfunction associated with schizophrenia. These novel observations might reveal the pathophysiology of the disorder, and indicate potential targets for antipsychotic drug therapy. Neuronal circuitry dynamics, such as network oscillations and sensory-gating processes, are conserved phylogenetically, which provides excellent opportunities for designing translational biomarkers. Whether preclinical, experimental compounds that impact on network oscillations and sensory processing (such as agonists and modulators of alpha7 nicotinic acetylcholine receptors) elicit the same neurophysiological events in schizophrenic patients and, subsequently, improve perception and cognitive functions will be determined when these drug candidates are available clinically.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16766049     DOI: 10.1016/j.tips.2006.05.005

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  17 in total

1.  Of rats and schizophrenia.

Authors:  Patricia Boksa
Journal:  J Psychiatry Neurosci       Date:  2007-01       Impact factor: 6.186

Review 2.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

3.  Altered Cortical and Hippocampal Excitability in TgF344-AD Rats Modeling Alzheimer's Disease Pathology.

Authors:  Milan Stoiljkovic; Craig Kelley; Bernardo Stutz; Tamas L Horvath; Mihály Hajós
Journal:  Cereb Cortex       Date:  2019-06-01       Impact factor: 5.357

Review 4.  Impact of ketamine on neuronal network dynamics: translational modeling of schizophrenia-relevant deficits.

Authors:  Bernat Kocsis; Ritchie E Brown; Robert W McCarley; Mihaly Hajos
Journal:  CNS Neurosci Ther       Date:  2013-04-24       Impact factor: 5.243

5.  TrkB signaling in parvalbumin-positive interneurons is critical for gamma-band network synchronization in hippocampus.

Authors:  Kang Zheng; Juan Ji An; Feng Yang; Weifeng Xu; Zhi-Qing David Xu; Jianyoung Wu; Tomas G M Hökfelt; André Fisahn; Baoji Xu; Bai Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-26       Impact factor: 11.205

6.  Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia.

Authors:  Yael Piontkewitz; Michal Arad; Ina Weiner
Journal:  Schizophr Bull       Date:  2010-05-03       Impact factor: 9.306

Review 7.  The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits.

Authors:  Andrés Buonanno
Journal:  Brain Res Bull       Date:  2010-08-03       Impact factor: 4.077

Review 8.  Effect of second-generation antipsychotics on cognition: current issues and future challenges.

Authors:  S Kristian Hill; Jeffrey R Bishop; Donna Palumbo; John A Sweeney
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

9.  NMDA antagonist and antipsychotic actions in cortico-subcortical circuits.

Authors:  Lucila Kargieman; Noemí Santana; Guadalupe Mengod; Pau Celada; Francesc Artigas
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 10.  Neurophysiological biomarkers for drug development in schizophrenia.

Authors:  Daniel C Javitt; Kevin M Spencer; Gunvant K Thaker; Georg Winterer; Mihály Hajós
Journal:  Nat Rev Drug Discov       Date:  2008-01       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.